SEARCH

SEARCH BY CITATION

References

  • 1
    Weed LL. Medical records that guide and teach. N Engl J Med. 1968; 278: 593600.
  • 2
    Wennberg JE, Gittelsohn AM. Small area variations in health care delivery. Science. 1973;183: 11028.
  • 3
    Chassin MR. Is health care ready for Six Sigma quality? Milbank Q. 1998;76510: 56591.
  • 4
    Eddy DM. The challenge. JAMA. 1990;263: 28790.
  • 5
    Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press; 2001.
  • 6
    Simborg DW, Starfield BH, Horn SD, Yourtee SA. Information factors affecting problem follow-up in ambulatory care. Med Care. 1976;14: 84856.
  • 7
    Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001;38: 210113.
  • 8
    Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol. 1999;83: 1A38A.
  • 9
    Khalil ME, Basher AW, Brown J, Edward J, Alhaddad IA. A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. J Am Coll Cardiol. 2001;37: 175764.
  • 10
    Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100: 23128.
  • 11
    Univasc [package insert]. Milwaukee, WI: Schwarz Pharma; 2001.
  • 12
    Lotensin [package insert]. East Hanover, NJ: Novartis; 2002.
  • 13
    Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327: 66977.
  • 14
    McAlister FA, Teo KK, Taher M, et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J. 1999;138: 8794.
  • 15
    Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: Wiley-Interscience; 2000.
  • 16
    Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355: 157581.
  • 17
    The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157: 241346.
  • 18
    Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334: 134955.
  • 19
    Hennekens CH, Buring JE. Epidemiology in Medicine. Boston, MA: Little, Brown and Company; 1987.
  • 20
    Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q. 1966;44 (suppl): 166206.